No Data
No Data
North China Pharmaceutical (600812.SH): Subsidiary receives government subsidy of 1.1 million yuan.
On June 24, Gelunhui reported that North China Pharmaceutical (600812.SH) and its subsidiaries received a total of 1,100,000.00 yuan in government subsidies related to income from June 17, 2024 to the date of this announcement. This accounts for 22.49% of the net income attributable to shareholders of the listed company in 2023.
North China Pharmaceutical Company.Ltd's (SHSE:600812) Business And Shares Still Trailing The Industry
North China Pharmaceutical Company.Ltd's (SHSE:600812) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now compared to the Pharmaceuticals industry in China, where a
North China Pharmaceutical (600812.SH) plans to register and issue short-term financing bonds and medium-term notes.
On June 5th, Gelunhui reported that North China Pharmaceutical (600812.SH) plans to apply to the National Interbank Funding Center to register and issue short-term financing bonds not exceeding RMB 2 billion yuan and medium-term notes not exceeding RMB 2 billion yuan in order to further expand financing channels, optimize financing structure, and reduce financing costs. The Bank of China will act as the intermediary trader.
North China Pharmaceutical (600812.SH) and its subsidiaries have received a government subsidy of 1.5 million RMB.
On June 4th, Gelonhui reported that North China Pharmaceutical (600812.SH) and its subsidiary companies received a total of RMB 1.5 million in government subsidies related to revenue from June 3, 2024, to the date of this announcement. This accounts for 30.67% of the net income attributable to shareholders of the listed company in 2023.
China Grants Marketing Approval for Ampicillin Sodium as Active Pharmaceutical Ingredient
China's state drug administrator granted North China Pharmaceutical (SHA:600812) chemical active pharmaceutical ingredient marketing approval for its ampicillin sodium, according to a Monday filing wi
North China Pharmaceutical Company.Ltd (SHSE:600812 Investor Three-year Losses Grow to 51% as the Stock Sheds CN¥412m This Past Week
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of North China Pharmaceutical Company.Ltd (SHSE:600812) have had an unfortunate run in the last three y
No Data